Two Sigma Advisers
ANTX icon

Two Sigma Advisers’s AN2 Therapeutics ANTX Stock Holding History

Two Sigma Advisers’s Portfolio ANTX Stock Details ANTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-264,900
Closed -$302K – 131
2025
Q4 		$302K Sell
264,900
-3,000
-1% -$3.5K ﹤0.01% 1981
2025
Q3 		$340K Sell
267,900
-1,700
-0.6% -$1.94K ﹤0.01% 1921
2025
Q2 		$286K Sell
269,600
-175,404
-39% -$209K ﹤0.01% 1982
2025
Q1 		$605K Sell
445,004
-83,296
-16% -$105K ﹤0.01% 1698
2024
Q4 		$729K Buy
528,300
+407,400
+337% +$494K ﹤0.01% 1615
2024
Q3 		$129K Sell
120,900
-13,800
-10% -$23.9K ﹤0.01% 2139
2024
Q2 		$290K Buy
+134,700
New +$321K ﹤0.01% 2081

Other funds holding ANTX

VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
AC
Almitas Capital Santa Monica, California $417M AUM 22.81% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Woodline Partners
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return

Two Sigma Advisers's ANTX Position: Q1 2026 in Review

Two Sigma Advisers sold out of AN2 Therapeutics (ANTX) in Q1 2026, closing a stake of 264,900 shares — an estimated $302K sold.

Two Sigma Advisers first reported a position in ANTX in Q2 2024 and held it in 7 quarters. The position peaked at $729K in Q4 2024. 52 funds tracked by Wall St. Rank hold ANTX as of Q1 2026.

  • Two Sigma Advisers reported no remaining AN2 Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Two Sigma Advisers sold 264,900 AN2 Therapeutics shares in Q1 2026, an estimated $302K.
  • Two Sigma Advisers first reported a position in AN2 Therapeutics in Q2 2024 and held it in 7 quarters.
  • Two Sigma Advisers's AN2 Therapeutics position peaked at $729K in Q4 2024.
  • 52 funds tracked by Wall St. Rank held AN2 Therapeutics as of Q1 2026.

Based on Two Sigma Advisers's 13F filing for Q1 2026.